Skip to main content

Table 1 Clinical and pathological characteristics of the patients.

From: A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

Parameter n (%)
Histological diagnosis*  
   IDC 67 (70.5)
   ILC 16 (16.8)
   Others 12 (12.6)
Histological grade  
   I 29 (55.8)
   II 19 (36.5)
   III 4 (7.7)
Tumor size (T)  
   T2 76 (80.0)
   T3-T4 19 (20.0)
Lymph node involvement (N)  
   N0 76 (80.0)
   N1-2 19 (20.0)
Stage  
   IIa 65 (68.4)
   IIb 20 (21.1)
   IIIa-IIIb 10 (10.5)
ER  
   Negative 5 (5.3)
   10-40% 8 (8.4)
   40-70% 25 (26.3)
   > 70% 57 (60.0)
PgR  
   Negative 28 (29.5)
   10-40% 18 (18.9)
   40-70% 24 (25.3)
   > 70% 25 (26.3)
HR**  
   ≤ 40% 10 (10.5)
   > 40% 85 (89.5)
HER2  
   Negative 39 (41.1)
   + 24 (25.3)
   ++ 22 (23.2)
   +++ 10 (10.5)
Ki67  
   Negative 40 (55.6)
   Positive 32 (44.4)
Response to letrozole  
   Non responders 60 (63.2)
   Responders 35 (36.8)
Progression status  
   No progression 77 (81.1)
   Progression 18 (18.9)
Surgery status  
   No surgery 30 (32.0)
   Surgery 65 (68.0)
  1. *IDC, Infiltrating ductal carcinoma; ILC, Infiltrating lobular carcinoma; Others (Mucinous, tubular and medullar carcinomas).
  2. **Hormonal status was considered as ≤ 40% when either estrogen and progesterone receptors were ≤ 40%, and as > 40% when at least one of the receptors were > 40%.